Post job

Explore jobs

Find specific jobs

Explore careers

Explore professions

Best companies

Explore companies

Working at Intra-Cellular Therapies

Zippia score 4.5

Overview

JobsSalaryRevenue

Reviews

CEO & Executives

Intra-Cellular Therapies overview

Industry
Pharmaceutical Manufacturing
Revenue
$680.9M
Headquarters
Employees
73
Founded in
Website
Organization type
Public
Social media
Intra-Cellular Therapies (ITI) is developing novel drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the Central Nervous System (CNS). We combine the efforts of medicinal chemists, pharmacologists, biologists and clinical development scientists into a vibrant team that translates world-class research expertise into novel drugs. The company's lead product, ITI-007 is a novel first-in-class 5-HT2A antagonist, Dopamine receptor phosphoprotein modulator (DPPM) designed to treat multiple deficits in patients with schizophrenia while lacking the side-effects of existing antipsychotic drugs. ITI has also developed a state of the art technology platform, called CNSProfile™ that is capable of generating a unique molecular signature for drug compounds. This profile provides us with a proprietary window into the intracellular action of CNS drugs or drug candidates. We use this tool to fingerprint the intracellular molecular actions of existing drugs and to drive our internal drug discovery and development. Our technology has also enabled the company to examine the toxic effects of brain damaging nerve agents, and as a result, we are involved in collaborative efforts with several military and contract organizations to develop antidotes to chemical warfare agents. Based upon our understanding of the Central Nervous System we have discovered novel drug candidates with promise for treating the panoply of symptoms associated with the transition from peri-menopausal to post-menopausal states. Intra-Cellular Therapies was founded in 2002 by Drs. Paul Greengard, Sharon Mates and Allen Fienberg. The company is headquartered in New York City.
Based in New York, NY, Intra-Cellular Therapies is a small manufacturing company with only 73 employees and an annual revenue of $680.9M.

Intra-Cellular Therapies's mission statement

To develop innovative treatments to improve the lives of individuals with neuropsychiatric and neurologic disorders in order to reduce the burden on patients and their caregivers.

In demand companies are hiring! Let Zippi apply for you!

Floating question marks illustration

5.0/5

Intra-Cellular Therapies employee reviews

Based on 1 ratings

Do you work at Intra-Cellular Therapies?

Help job seekers learn about working at Intra-Cellular Therapies

On this page

Be the first to review Intra-Cellular Therapies

Anonymously rate your employee experience

Your opinion can help other job seekers

Do you like working at Intra-Cellular Therapies?

The team at Intra-Cellular Therapies

  • The founders of Intra-Cellular Therapies are Sharon Mates, Allen Fienberg, Nobel Laureate and Paul Greengard.
  • The key people at Intra-Cellular Therapies are Sharon Mates, Allen Fienberg and Nobel Laureate.
Key people
Sharon Mates
Allen Fienberg
Nobel Laureate
Paul Greengard

Intra-Cellular Therapies rankings

Intra-Cellular Therapies is ranked #52 on the Best Manufacturing companies to work for in New York list. Zippia's Best Places to Work lists provide unbiased, data-based evaluations of companies. Rankings are based on government and proprietary data on salaries, company financial health, and employee diversity.

Read more about how we rank companies.

Intra-Cellular Therapies salaries

Average Intra-Cellular Therapies salary
$45,580
yearly
$21.91 hourly
Updated March 14, 2024

Rate the fairness of Intra-Cellular Therapies' compensation policies.

Zippia waving zebra

Do you work at Intra-Cellular Therapies?

Is Intra-Cellular Therapies' workforce diverse and inclusive?

Intra-Cellular Therapies financial performance

9.9
Performance score

We calculated the performance score of companies by measuring multiple factors, including revenue, longevity, and stock market performance.

Intra-Cellular Therapies currently has 250.3M in revenue. Intra-Cellular Therapies's most recent quarter produced 126.2m (q3'2023).

Intra-Cellular Therapies annual revenue

$681M
$545M
$409M
$272M
$136M
$0
2019
2020
2021
2022
2023
2024

Are you an executive, HR leader, or brand manager at Intra-Cellular Therapies?

Claiming and updating your company profile on Zippia is free and easy.

Intra-Cellular Therapies FAQs

Have more questions? See all answers to common company questions.

Search for jobs

Most common jobs at Intra-Cellular Therapies

Cities with Intra-Cellular Therapies jobs

Related companies

Related company jobs

    Updated March 14, 2024

    Zippia gives an in-depth look into the details of Intra-Cellular Therapies, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Intra-Cellular Therapies. The employee data is based on information from people who have self-reported their past or current employments at Intra-Cellular Therapies. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Intra-Cellular Therapies. The data presented on this page does not represent the view of Intra-Cellular Therapies and its employees or that of Zippia.

    Intra-Cellular Therapies may also be known as or be related to INTRA CELLULAR THERAPIES INC., Intra Cellular Therapies, Intra-Cellular Therapies, Intra-Cellular Therapies Inc, Intra-Cellular Therapies, Inc. and Intracellular Therapies Inc.